Warner Chilcott, LEO Pharma receive FDA approval for Taclonex

By Lisa Kerner

Erie, Pa., Jan. 10 - Warner Chilcott and LEO Pharma received approval from the U.S. Food and Drug Administration for their new drug application for Taclonex, a topical ointment for the treatment of psoriasis.

Warner Chilcott expects to launch Taclonex in the first half of this year.

Warner Chilcott acquired the U.S. marketing rights for Dovonex, a non-steroidal topical treatment for psoriasis, from Bristol-Myers Squibb Co. as of Jan. 1. Warner Chilcott is LEO Pharma's exclusive licensee of Taclonex and Dovonex in the United States. Taclonex is sold outside the United States as Dovobet or Daivobet.

Psoriasis is a chronic, inflammatory skin disease with no cure. More than 4.5 million adults in the United States have been diagnosed with psoriasis, and approximately 150,000 new cases are diagnosed each year, according to a company news release.

Warner Chilcott, with U.S. offices in Rockaway, N.J., is a specialty pharmaceutical company.

LEO Pharma is a research-based pharmaceutical company with headquarters in Ballerup, Denmark.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.